Synapse - Myeloma

Search Within

Myeloma

Results (1005)

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial

Meeting Abstract

Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
Blood (2024)

Fulltext@MSK | Save

A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mian, H.; Baljevic, M.; Magen, H.; Gatt, M. E.; Mazza, I. A.; Searle, E.; Lichtman, E. I.; McKay, J. T.; Plesner, T.; Rodriguez, C.; more...
Blood (2024)

Fulltext@MSK | Save

Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)

Meeting Abstract

Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
Blood (2024)

Fulltext@MSK | Save

Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies

Meeting Abstract

Richter, J.; Thomas, S. K.; Krishnan, A. Y.; Laubach, J. P.; Cohen, A. D.; Trudel, S.; Costa, L. J.; Bahlis, N. J.; Forsberg, P. A.; Kaedbey, R.; more...
Blood (2024)

Fulltext@MSK | Save

CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes

Meeting Abstract

Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
Blood (2024)

Fulltext@MSK | Save

Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center

Meeting Abstract

Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
Blood (2024)

Fulltext@MSK | Save

Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those having European ancestry

Meeting Abstract

Maclachlan, K. H.; Papadimitriou, M.; Blaney, P.; Shekarkhand, T.; Chu, T. R.; Poos, A. M.; Brown, E.; Hoering, A.; Diamond, B.; Ziccheddu, B.; more...
Blood (2024)

Fulltext@MSK | Save

Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance

Meeting Abstract

Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; Garcés, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
Blood (2024)

Fulltext@MSK | Save

A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma

Meeting Abstract

Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
Blood (2024)

Fulltext@MSK | Save

ABBV-383 plus daratumumab-dexamethasone in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Meeting Abstract

Rodriguez, C.; Mielnik, M.; Kazandjian, D.; Janowski, W.; Low, M. S. Y.; Pianko, M.; Yuda, J.; Van Der Weyden, C.; Anderson, L. D. Jr; Banerjee, R.; more...
Blood (2024)

Fulltext@MSK | Save